Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.45B | 1.40B | 1.36B | 1.39B | 1.42B | 1.16B |
Gross Profit | 1.19B | 1.20B | 1.18B | 1.21B | 1.23B | 980.43M |
EBITDA | 338.15M | 319.10M | 331.97M | 398.39M | 681.68M | 363.27M |
Net Income | 66.09M | 63.05M | 41.50M | 63.76M | 496.71M | 150.67M |
Balance Sheet | ||||||
Total Assets | 3.52B | 3.70B | 3.47B | 3.53B | 3.76B | 3.67B |
Cash, Cash Equivalents and Short-Term Investments | 457.26M | 505.88M | 764.72M | 711.21M | 924.04M | 243.31M |
Total Debt | 865.38M | 894.75M | 1.00B | 1.06B | 1.17B | 1.71B |
Total Liabilities | 1.68B | 1.89B | 1.58B | 1.64B | 1.80B | 2.45B |
Stockholders Equity | 1.84B | 1.81B | 1.89B | 1.89B | 1.96B | 1.21B |
Cash Flow | ||||||
Free Cash Flow | 233.13M | 283.68M | 211.23M | 230.24M | 401.75M | 384.41M |
Operating Cash Flow | 341.88M | 390.31M | 319.96M | 336.44M | 515.57M | 480.08M |
Investing Cash Flow | -285.92M | -297.45M | -127.41M | -220.77M | 59.09M | -586.22M |
Financing Cash Flow | -296.12M | -320.99M | -114.79M | -140.83M | -113.59M | -234.63M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $1.49B | 25.99 | 5.52% | ― | 14.39% | 1946.11% | |
74 Outperform | $1.53B | 24.70 | 3.56% | ― | 5.94% | -8.89% | |
74 Outperform | $1.35B | 10.11 | 12.79% | ― | -0.40% | 36.44% | |
74 Outperform | $3.11B | 77.69 | 5.82% | ― | 5.52% | ― | |
73 Outperform | $1.48B | 492.79 | -0.32% | ― | 9.56% | ― | |
64 Neutral | $846.88M | 192.98 | 2.04% | ― | 78.27% | ― | |
60 Neutral | $42.79B | 1.96 | -11.10% | 4.01% | 1.89% | -41.77% |
On August 6, 2025, Ziff Davis reported its second quarter financial results for 2025, highlighting a 9.8% increase in quarterly revenues to $352.2 million compared to the previous year. Despite a decrease in net income, the company achieved its strongest revenue growth since 2021, driven by its Connectivity and Health & Wellness segments. The company also reaffirmed its guidance for the fiscal year 2025, indicating confidence in its ongoing operations and market positioning.